What Deutsche Biotech Innovativ does

Deutsche Biotech Innovativ AG (DBI AG) was a German publicly listed biotechnology investment holding company headquartered in Hennigsdorf near Berlin. Founded in 2009 as Venetus Beteiligungen AG and rebranded to its current name in August 2014, DBI AG operated as a specialized holding entity that acquired minority equity stakes in early- and mid-stage biotechnology companies developing drug candidates for severe unmet medical needs, including sepsis and septic shock, Alzheimer's disease, cardiogenic shock, cancer, and breast cancer prevention.

DBI AG's investment thesis centered on a distinctive methodology: analyzing blood samples from diseased patients to identify disease-relevant drug targets before backing the development of specific therapeutic candidates. Its portfolio included AdrenoMed AG (10.28% stake, developing Enibarcimab/Adrecizumab for septic shock with completed Phase II AdrenOSS-2 trial in 301 patients), PAM-Theragnostics GmbH (Alzheimer's diagnostics and therapy via PeptidylGlycin-Alpha-Amidating Monooxygenase enzyme technology), 4TEEN4 Pharmaceuticals GmbH (Invobenitug for organ failure in cardiogenic shock), Sphingotec GmbH (diagnostic biomarkers for kidney function and vasodilation), and earlier holdings in AngioBiomed GmbH and Belano Medical AG. The holding company generated returns through capital gains, dividends, and exit proceeds from these investments, with shares previously listed on the Düsseldorf, Frankfurt, and Berlin exchanges.

Following the delisting of its shares from the Freiverkehr exchanges on September 30, 2024, DBI AG entered liquidation by shareholder resolution dated March 31, 2026. Dr. Metod Miklus, who had served as COO since 2020 succeeding Dr. Andreas Bergmann as CSO, was appointed sole liquidator and sole executive board member. The company is currently divesting all remaining holdings: stakes in 4TEEN4 Pharmaceuticals and Sphingotec were sold in 2025, PAM-Theragnostics was divested in July 2026, and the AdrenoMed AG stake remains listed for sale. Two earlier portfolio holdings (Belano Medical AG and AngioBiomed GmbH) were written off due to liquidation or insolvency.

Name

Deutsche Biotech Innovativ

Legal name

Deutsche Biotech Innovativ AG

Website

https://dbi-ag.de

Company type

Private

Founded year

2009

Operating status

Closed

Headcount range

11–50 employees

Short description

Deutsche Biotech Innovativ AG (DBI AG) was a German listed biotech investment holding company that acquired minority stakes in firms developing drug candidates for diseases with high unmet medical needs. The company is now in liquidation, divesting all remaining holdings.

Ownership category

akta.pro rank

Product category

Biotechnology Investment Holding

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Biotechnology investment
• Biotech portfolio management
• Drug development funding
• Biomarker drug discovery
• Life sciences venture

Headquarters

HQ city

Hennigsdorf

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others

Revenue model

1. Investment Returns from Portfolio Companies: DBI AG generated returns through capital gains, dividends, and exit proceeds from its investments in biotechnology companies. The company invested in firms developing innovative drug candidates with high uniqueness and blockbuster potential for unmet medical needs. The company is now in liquidation and seeking to fully divest all remaining holdings.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Deutsche Biotech Innovativ AG was a publicly listed biotechnology investment holding company that acquired and held minority stakes in biotech companies developing innovative drug candidates for severe diseases with high unmet medical need. The company identified drug targets by analysing blood from diseased patients, then supported portfolio companies developing antibodies and therapeutics in sepsis, cardiogenic shock, Alzheimer's disease, kidney disease, and cancer. As of March 31, 2026 the company is in liquidation and divesting its remaining holdings.

Product overview

Deutsche Biotech Innovativ AG is a biotechnology investment company that invests in innovative biotech companies developing drugs for unmet medical needs. The company operated a portfolio of three drug candidates: Enibarcimab (Adrecizumab) for sepsis/septic shock treatment, AB2302 for cancer therapy, and DB1RA for breast cancer prevention. The company also held stakes in Adrenomed AG, PAM-Theragnostics GmbH, Sphingotec GmbH, and 4TEEN4 Pharmaceuticals GmbH. Following shareholder resolution on March 31, 2026, the company entered liquidation and is divesting all remaining holdings.

Differentiator

Problem solved

Functional benefit

Products and services

• Enibarcimab (Adrecizumab) Humanized monoclonal antibody developed through portfolio company AdrenoMed AG that specifically binds the vasoactive peptide hormone Adrenomedullin without blocking its biological activity, intended to restore vascular integrity in patients with septic shock. Successfully completed Phase II clinical trial (AdrenOSS-2) with 301 patients confirming safety, tolerability, and efficacy.
• AB2302 Cancer therapy drug candidate for anti-tumor treatment developed via portfolio company AngioBiomed GmbH.
• DB1RA Drug candidate for breast cancer prevention that blocks the Neurokinin-1 receptor to inhibit cell division and cell migration, causing cancer cell death.

Quantifiable outcome

• Phase II clinical trial success with Enibarcimab (Adrecizumab) - 301 patients with septic shock; confirmed safety, tolerability, and efficacy regarding mortality and mode of action
• +1 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered minor and core.

• PAM-Theragnostics GmbHminorStrategic or Co-development Partner · 1 January 2020A biotech startup founded in 2020 focused on developing diagnostic methods and therapeutic strategies for early detection of age-related vascular diseases, particularly Alzheimer's disease, through the PeptidylGlycin-Alpha-Amidating Monooxygenase (PAM) enzyme. DBI divested its stake in July 2026.
• AdrenoMed AGcoreStrategic or Co-development Partner · 1 January 2009AdrenoMed AG is the most important portfolio company of DBI AG, focused on developing Enibarcimab (formerly Adrecizumab), a novel antibody-based therapy targeting Adrenomedullin for the treatment of septic shock. DBI held 10.28% stake, now listed for sale. The company successfully completed Phase II clinical trial with 301 patients.

Scale indicators3 records

Recent moves10 records

Broad incumbents

• Evotec SE: German-listed drug discovery and development company operating a broad platform across multiple therapeutic areas including immunology, oncology, and central nervous system disorders. Comparable as a German-headquartered biotech operating company, though Evotec operates integrated discovery platforms rather than minority investment exposure.
• LSP (Life Sciences Partners): European life sciences-focused venture capital firm managing multiple funds investing in European biotech companies. Comparable to DBI's investment approach of funding biotech companies targeting unmet medical needs, though operating as a fund manager rather than a listed holding company.

Direct peers

• BB Biotech AG: Swiss-domiciled, listed investment holding company that holds concentrated positions in publicly traded biotechnology companies. BB Biotech is the closest direct peer in business model (listed biotech investment holding), geography (German-speaking Europe), and target asset class, though it focuses on public equities rather than private portfolio companies.
• Arix Bioscience plc: UK-listed bioscience investment company focused on building and developing breakthrough biotech companies. Similar business model of holding strategic stakes in private biotech companies, with comparable European geographic footprint and therapeutic focus areas.
• Worldwide Healthcare Trust PLC: UK-listed investment trust focused on global healthcare and biotechnology equities, including small-cap and mid-cap biotech. Comparable as a listed investment vehicle targeting the same biotech subsector, though typically exposed to public equities rather than private stakes.
• International Biotech Trust plc: UK-listed investment trust providing investors with diversified exposure to listed and unlisted biotechnology companies. Directly comparable to DBI as a publicly listed biotech investment vehicle targeting companies addressing unmet medical needs.
• HBM Healthcare Investments AG: Swiss-listed healthcare and biotechnology investment company focused on private and public equity in the human medicine, biotechnology, medical technology, and diagnostics sectors. Highly comparable to DBI in that it holds minority stakes in private biotech companies developing drugs for unmet medical needs, and is operated as a publicly listed investment holding company.

Market position

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/deutsche-biotech-innovativ-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deutsche Biotech Innovativ